Last reviewed 2026-05-26 · How we verify

Thiocarb (DITIOCARB)

Phase 2 active Small molecule ✓ Verified May 2026

Thiocarb (generic name: DITIOCARB) is a ditiocarb drug. It is currently in Phase 2 development.

Thiocarb works by inhibiting the activity of Gasdermin-D, a protein that plays a key role in the inflammatory response and cell death.

Thiocarb is a small molecule with the chemical name diethyldithiocarbamate. It has been studied in clinical trials for various conditions, including metastatic melanoma, glioma, glioblastoma, and stage IV melanoma, in combination with disulfiram, arsenic trioxide, and copper.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DITIOCARB
Drug class	ditiocarb
Target	Cytochrome P450 2E1, Gasdermin-D, Histone-lysine N-methyltransferase EHMT1
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of Gasdermin-D like a switch that turns on inflammation and cell death. Thiocarb is like a key that locks this switch, preventing it from being turned on and reducing inflammation and cell death. This can help to treat conditions where inflammation and cell death are a problem.

Approved indications

No approved indications tracked.

Common side effects

Radiation inflammation

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Thiocarb CI brief — competitive landscape report
Thiocarb updates RSS · CI watch RSS

Frequently asked questions about Thiocarb

What is Thiocarb?

Thiocarb (DITIOCARB) is a ditiocarb drug.

How does Thiocarb work?

Thiocarb works by inhibiting the activity of Gasdermin-D, a protein that plays a key role in the inflammatory response and cell death.

What is the generic name of Thiocarb?

DITIOCARB is the generic (nonproprietary) name of Thiocarb.

What drug class is Thiocarb in?

Thiocarb belongs to the ditiocarb class. See all ditiocarb drugs at /class/ditiocarb.

What development phase is Thiocarb in?

Thiocarb is in Phase 2.

What are the side effects of Thiocarb?

Common side effects of Thiocarb include Radiation inflammation.

What does Thiocarb target?

Thiocarb targets Cytochrome P450 2E1, Gasdermin-D, Histone-lysine N-methyltransferase EHMT1 and is a ditiocarb.

Drug class: All ditiocarb drugs
Target: All drugs targeting Cytochrome P450 2E1, Gasdermin-D, Histone-lysine N-methyltransferase EHMT1
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing